La Fondation Bill & Melinda Gates annonce un soutien supplémentaire pour promouvoir la R&D locale. Appels à propositions

BRUXELLES25 octobre 2022 /PRNewswire/ — La Fondation Bill & Melinda Gates a annoncé aujourd’hui une série d’initiatives et un appel à propositions en vue de faire progresser l’innovation locale qui soutient les travaux de scientifiques et de chercheurs dans les économies en développement. L’annonce a été faite lors de la réunion annuelle de Grand Challenges plus tôt aujourd’hui.

La réunion de cette année se concentre sur les enseignements tirés de la pandémie de COVID-19, qui a mis en évidence la nécessité de plateformes de R&D à fort impact, de partenariats et de politiques qui comblent efficacement le fossé existant entre l’innovation et l’accès équitable. La réunion rapproche des chercheurs du monde entier pour partager leurs travaux, en apprendre davantage sur les avancées de pointe dans le domaine des soins de santé et permettre une collaboration avec d’autres chercheurs.

« L’équité en santé ne devrait pas uniquement être un énoncé de la raison pour laquelle nous faisons ce travail. Elle devrait guider la façon dont nous le réalisons », a déclaré Kedest Tesfagiorgis, directeur adjoint des Partenariats mondiaux et des grands défis à la Fondation Bill & Melinda Gates. « Lorsque nous soutenons l’innovation locale, nous maximisons l’impact en mettant en lumière différents types de connaissances et de perspectives. »

Dans le cadre de l’Appel mondial à l’action de Grand Challenges, une initiative sur 10 ans annoncée lors de la réunion de l’année dernière pour aider à s’assurer que les scientifiques et les institutions des pays à revenu faible et intermédiaire (PRFI) jouent un rôle central dans l’élaboration du programme mondial de R&D, deux nouvelles initiatives Grand Challenges ont été annoncée par la fondation :

  • La surveillance génomique des agents pathogènes et l’immunologie en Asie Il s’agit d’une invitation à soumission par les chercheurs en Asie du Sud et du Sud-Est pour concevoir et piloter un programme de surveillance génomique ou de développer des capacités en immunologie et séquençage immunitaire du SRAS-CoV-2 afin d’éclairer la réponse épidémique. Un montant allant jusqu’à 300 000 $ par année pour une période maximale de deux ans seront disponibles pour chaque projet, avec un financement supplémentaire potentiel pour les projets qui mettent l’accent sur la recherche d’anticorps monoclonaux.
  • Le renforcement des capacités de modélisation des données pour l’égalité des sexes  Il s’agit d’un appel à propositions lancé aux chercheurs de pays à revenu faible ou intermédiaire pour des projets visant à éliminer les disparités et les lacunes affectant les femmes et les filles dans le domaine de la santé. Cette initiative est axée sur des approches novatrices de modélisation pour faire progresser l’égalité des sexes. Chaque projet recevra jusqu’à 500 000 $ sur une période d’un à trois ans.

« Les sociétés mesurent ce qu’elles valorisent, et pour une grande partie de l’histoire, la société n’a pas valorisé les femmes. Cela signifie que nous essayons de relever des défis mondiaux en matière de santé et de développement sans disposer de toutes les informations nécessaires », a déclaré Anita Zaidi, présidente du département de l’Égalité des sexes à la Fondation Bill & Melinda Gates. « Il est grand temps de placer les femmes et les filles au centre de la modélisation des données qui guide nos solutions. »

En partenariat avec l’Initiative Chan Zuckerberg (CZI), la fondation accordera également des subventions aux chercheurs qui étudient et détectent les agents pathogènes émergents dans les PRFI. Les chercheurs recevront jusqu’à 200 000 $ chacun, pour une période maximale de deux ans, ainsi que le soutien opérationnel et une formation technique du Biohub Chan Zuckerberg  (CZ Biohub). Cet engagement de financement s’appuie sur un partenariat de 2018 entre la fondation, CZI et le CZ Biohub, qui se concentre sur le renforcement des capacités métagénomiques dans les PRFI par le biais d’une Initiative mondiale Grand Challenges.

La réunion annuelle de Grand Challenges 2022 à Bruxelles est organisée par Global Grand Challenges et la Commission européenne, et est coparrainée par Grands Défis Canada, USAID, Wellcome et la Fondation Bill & Melinda Gates.

L’événement de deux jours réunit des dizaines de leaders du paysage mondial de l’innovation en santé, ainsi que des dirigeants de la Fondation Gates, notamment Bill Gates (coprésident et administrateur), Anita Zaidi et Trevor Mundel (Président, Division de la santé mondiale). Les séances plénières seront publiées peu après la réunion sur le site grandchallenges.org/annual-meeting.

À propos de Grand Challenges

La Fondation Bill & Melinda Gates reconnaît que la résolution des défis les plus urgents en matière de santé et de développement mondiaux nécessite que davantage des esprits les plus brillants du monde y travaillent. La série d’initiatives Grand Challenges cherche à mobiliser des innovateurs du monde entier pour aider à résoudre ces défis. Les initiatives Grand Challenges sont unies par leur volonté de favoriser l’innovation, d’orienter la recherche là où elle aura le plus grand impact et d’aider ceux qui en ont le plus besoin. Pour en savoir plus, visitez le site grandchallenges.org.

À propos de la Fondation Bill & Melinda Gates

Guidée par la conviction que chaque vie a la même valeur, la Fondation Bill & Melinda Gates s’efforce d’aider toutes les personnes à mener une vie saine et productive. Dans les pays en développement, elle vise à améliorer la santé des populations et à leur donner la possibilité de ne plus souffrir de la faim et de l’extrême pauvreté. Aux États-Unis, elle vise à faire en sorte que toutes les personnes, en particulier celles qui ont le moins de ressources, aient accès aux opportunités dont elles ont besoin pour réussir à l’école et dans la vie. Basée à Seattle, Washington, la fondation est dirigée par son PDG Mark Suzman, sous la direction des coprésidents Bill Gates et Melinda French Gates et du Conseil d’administration.

Contact pour les médias : media@gatesfoundation.org

IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

Adidas Ends Partnership With Kanye West Over Antisemitic Remarks

Adidas ended its lucrative partnership with the rapper Ye, formerly known as Kanye West, over his offensive and antisemitic remarks, which drew widespread criticism from Jewish groups, celebrities and others on social media who said the German sportswear company was being too slow to act.

The sneaker giant became the latest company to cut ties with Ye, who was suspended from Twitter and Instagram this month over antisemitic posts that the social networks said violated their policies. The outcry swelled after demonstrators on a Los Angeles overpass unfurled a banner Saturday praising Ye’s antisemitic comments.

Adidas said it expected to take a hit of up to 250 million euros ($246 million) to its net income this year from the decision to immediately stop production of its line of Yeezy products and stop payments to Ye and his companies.

“Adidas does not tolerate antisemitism and any other sort of hate speech,” the company said in a statement Tuesday. “Ye’s recent comments and actions have been unacceptable, hateful and dangerous, and they violate the company’s values of diversity and inclusion, mutual respect and fairness.”

Jewish groups, noting Adidas’ past links to the Nazi regime, said the decision was overdue. The World Jewish Congress noted that during World War II, Adidas factories “produced supplies and weapons for the Nazi regime, using slave labor.”
“I would have liked a clear stance earlier from a German company that also was entangled with the Nazi regime,” said Josef Schuster, president of the Central Council of Jews in Germany, the main Jewish group in the country where Adidas is headquartered.

For weeks, Ye has made antisemitic comments in interviews and social media, including a Twitter post earlier this month that he would soon go “death con 3 on JEWISH PEOPLE,” an apparent reference to the U.S. defense readiness condition scale known as DEFCON.

The rapper has alienated even ardent fans in recent years, teasing and long tinkering with albums that haven’t been met with the critical or commercial success of his earlier recordings. Those close to him, like ex-wife Kim Kardashian and her family, have ceased publicly defending him after the couple’s bitter divorce and his unsettling posts about her recent relationship with comedian Pete Davidson.

Ye has told Bloomberg that he plans to cut ties with his corporate suppliers. After he was suspended from Twitter and Facebook, Ye offered to buy conservative social network Parler.

An email message sent to a representative for Ye was not immediately returned.
Adidas, whose CEO Kasper Rorsted is stepping down next year, said it reached its decision after conducting a “thorough review” of its partnership with Ye, whose talent agency, CAA, as well as Balenciaga fashion house had already dropped the rapper.

Despite the growing controversy, Allen Adamson, co-founder of marketing consultancy Metaforce, believes that Adidas’ delayed response was “understandable.”

“It’s a hugely profitable, edgy brand association,” Adamson said. “The positives are so substantial in terms of the audience it appeals to — younger, urban, trendsetters, the size of the business. I’m sure they were hoping against hope that he would apologize and try to make this right.”

Adamson noted that Adidas was facing pressure from everywhere including customers, employees and stakeholders.

“There’s the short-term profits of selling shoes, and then there is the long-term equity of the Adidas brand,” he said.

In the hours before the announcement, some Adidas employees in the United States had spoken out on social media about the company’s inaction.

Sarah Camhi, a director of trade marketing at the company who described herself as Jewish, said in a LinkedIn post that she felt “anything but included” as Adidas.

“remained quiet; both internally to employees as well as externally to our customers” for two weeks after Ye made his antisemitic remarks.

The rapper, who has won 24 Grammy Awards, has been steadily losing audience on radio and even his streaming numbers have declined slightly over the last month. According to data provided by Luminate, an entertainment data and insights company whose data powers the Billboard music charts, his airplay audience slipped from 8 million in the week ending Sept. 22, to 5.4 million in the week ending on Oct. 20. The popularity of his songs on streaming on demand also went down in the same period, from 97 million to 88.2 million, about a 9% drop.

Ye has earned more of a reputation for stirring up controversy since 2016, when he was hospitalized in Los Angeles because of what his team called stress and exhaustion. It was later revealed that he had been diagnosed with bipolar disorder.

He recently suggested slavery was a choice and called the COVID-19 vaccine the “mark of the beast,” among other comments. He also was criticized for wearing a “White Lives Matter” T-shirt to his Yeezy collection show in Paris.

MRC studio announced Monday that it is shelving a complete documentary about the rapper. JPMorganChase and Ye have ended their business relationship, although the banking breakup was in the works even before Ye’s antisemitic comments.

Gap said Tuesday that it is also taking immediate steps to remove Yeezy Gap products from its stores and has shut down yeezygap.com in light of West’s comments. The clothing retailer said that in September it was ending their relationship but at the time, it said that it planned to continue to sell Yeezy Gap products that were in the pipeline.

Jewish groups have pointed to the danger of the rapper’s comments at a time of rising antisemitism. Such incidents in the U.S. reached an all-time high last year, the Anti-Defamation League said in a letter to Adidas last week urging it to break with Ye.

Jonathan Greenblatt, CEO of the Anti-Defamation League, applauded the company’s decision to drop Ye.

“This is a very positive outcome,” he said in a statement Tuesday. “It illustrates that antisemitism is unacceptable and creates consequences.”
The saga of Ye, not just with Adidas but with brands like Gap and Balenciaga, underscores the importance of vetting celebrities thoroughly and avoiding those who are “overly controversial or unstable,” said Neil Saunders, managing director of GlobalData Retail.

“Companies or brands that fail to heed this will get stung, especially if they become overly reliant on a difficult personality to drive their business,” Saunders said.

Source: Voice of America

Europe’s Bees Stung by Climate, Pesticides and Parasites

Bees pollinate 71 of the 100 crop species that provide 90% of food worldwide. They also pollinate wild plants, helping sustain biodiversity and the beauty of the natural world.

But climate change, pesticides and parasites are taking a terrible toll on bees, and they need protecting, said European beekeepers, who held their annual congress in Quimper, western France, this week.

The congress, which said some European beekeepers were suffering “significant mortalities and catastrophic harvests due to difficult climatic conditions,” was an opportunity for beekeepers and scientists to respond to the major concerns.

The European Union, the world’s second-largest importer of honey, currently produces just 60% of what it consumes.

French beekeepers, for example, expect to harvest between 12,000 and 14,000 metric tons of honey this year, far lower than the 30,000 tons they harvested in the 1990s, according to the National Union of French Beekeepers (UNAF).

“I’ve been fighting for bees for 30 years, but if I had to choose now, I don’t know if I’d become a beekeeper,” said UNAF spokesman Henri Clement, who has 200 hives in the mountainous Cevennes region in southeastern France.

Clement is 62 and not far off retiring.

“But it’s not much fun for young people who want to take up the profession,” he said.

Many of the topics buzzing around the congress were evidence of this — pesticides, climate change, and Asian hornets, parasitic varroa mites and hive beetles, all invasive alien species in Europe.

Challenges includes rain, drought

With climate change, “the bigger issue is just the erratic weather and rain patterns, drought and things like that,” said U.S. entomologist Jeff Pettis, president of Apimondia, an international federation of beekeeping associations in 110 countries.

“In certain places, the plants had been used to a certain temperature. And now it goes up, and you have a hot dry summer, and there are no flowers,” Pettis told AFP.

No flowers means no pollen, which means bees dying of hunger.

Climate scientists say human-induced global heating is intensifying extreme weather events such as flooding, and heatwaves that exacerbate wildfires.

“The fires seem to be a big issue,” Pettis said. “They come sporadically, and we lose hives directly from flooding and fires.

Pettis, a former scientist at the U.S. Department of Agriculture, published a study in 2016 on the quality of pollen produced by goldenrod, a hardy perennial also known as solidago that produces a myriad of small yellow daisy-like flowers.

The study showed that the more carbon dioxide — a greenhouse gas — that accumulates in the atmosphere, the lower the amount of protein in goldenrod pollen.

North America bees are dependent on nourishment from goldenrod pollen to get through the winter, Pettis said.

“Getting inferior food … should affect wintering. It could happen with other pollen sources. We don’t know.”

As in France, 30% to 40% of hives in the United States are dying every winter, Pettis said, decimated by varroa mites, pesticides and the destruction of wild spaces where wild plants grow

“Today, there are even American startups that are developing drones to pollinize plants in the place of bees. It’s utterly appalling,” said Clement.

Toxic threat

Toxic pesticides are another factor decimating bee colonies and other pollinating insects.

French molecular biophysics scientist Jean-Marc Bonmatin said parasites such as varroa were “boosted by the presence of neonicotinide pesticides, which directly poison pollinators.”

Neonicotinoids, chemically similar to nicotine, are systemic pesticides.

Unlike contact pesticides, which remain on the surface of the treated leaves, systemic pesticides are taken up by the plant and transported to its leaves, flowers, roots and stems, as well as to its pollen and nectar.

These toxic substances can remain in the soil for between five and 30 years, Bonmatin said.

The EU restricted the use of three neonicotinoids — but not all — in 2013 and banned them outright in 2018.

But since 2013, several EU states have repeatedly granted “emergency authorizations” to use noxious insecticides on major crops.

He said open-source software called Toxibee was being launched soon to help farmers protect bees by identifying the least toxic molecules to use on their crops.

“Before they spray the crops with pesticides, they can try to limit their noxious effect,” he said. “Because what kills bees will one day damage people’s health, too.”

Pettis strove, however, to remain upbeat, pointing to some of the ways people can help bees.

“[We should] diversify agriculture and try not [to] be driven by chemically dependent agriculture, support organic and more sustainable farming.”

He also stressed the incredible resistance of some bee species, helped by factors in the natural world.

He cited the example of a black bee found on the Ile de Groix in Brittany, which has survived varroa attacks without beekeepers treating them for mites or giving them supplementary feeding.

“We think the bees are dependent on us, but in reality, they survive pretty well even without us,” he said. “And you still have the beauty of the bees. It’s such a good thing to work with bees.”

Source: Voice of America

 IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

La Plateforme de Yoga française Shiksha® lance son Application et son Réseau Social membre

PARIS , 25 octobre 2022 /PRNewswire/ — Shiksha s’adresse à tous les pratiquants, débutants ou confirmés, qui aspirent à une pratique plus régulière et moins contraignante du yoga. Shiksha leur permet d’améliorer leur pratique personnelle du yoga ou de développer leurs compétences pédagogiques, en qualité de Professeur de yoga.

L’application donne accès à des cours de yoga en ligne, accessibles à la demande ou en direct, pour toutes les personnes recherchant davantage de qualité, de liberté et de commodité dans la découverte ou dans l’approfondissement de sa pratique. Shiksha propose également de nombreuses ressources téléchargeables et MasterClass (e-learning) à destination des professionnels de l’enseignement. Grâce à l’application, les utilisateurs peuvent notamment télécharger les contenus sur leur appareil, les regarder en mode hors connexion et créer leurs propres playlists personnalisées. Les membres de la tribu peuvent échanger entre-eux grâce à un réseau social interne réservé aux membres, y publier leur propres contenus (photos, publications) et notifier instantanément d’autres membres, grâce aux notifications Push par @identifiant utilisateur.

Shiksha se distingue notamment par la qualité éditoriale et technique de ses programmes, présentés sous forme de séries thématiques ou de MasterClass, et réalisés avec des moyens de production professionnels. Shiksha se base sur la technologie de streaming leader du marché (identique à Netflix), afin de garantir une expérience fluide et sans artefacts, quelle que soit la nature de la connexion côté utilisateur. Les cours hebdomadaires diffusés en lives, via un flux HD 1080p, proposent ainsi une expérience immersive et de qualité broadcast.

Shiksha propose une formule découverte totalement gratuite, pour accéder à des séances de méditation hebdomadaires diffusées en direct tous les mercredis matins. Le catalogue de plus de 800 vidéos est quant à lui accessible au moyen d’un abonnement mensuel au tarif de 16,99€/mois. Une formule annuelle à 149,99€ permet de réaliser une économie équivalente à 4 mois d’abonnement, (soit 12,50€/mois). Les abonnements démarrent après une période de gratuité de 14 jours, pendant lesquels l’utilisateur peut librement résilier son abonnement. Les accès aux MasterClass et aux cours en direct sont également possibles par achat unitaire (sans abonnement). Le code SHIKSHA2022, valable pour tout premier abonnement mensuel souscrit via le site Web uniquement, offre 2 mois gratuits jusqu’au 31/12/2022.

Visitez notre site Web : https://shiksha.yoga

Téléchargez l’application mobile :

Contact: namaste@shiksha.yoga

Photo – https://mma.prnewswire.com/media/1926478/Shiksha_Yoga_App.jpg